Developing next-generation biological drugs for treating wounds in skin and mucosa
The innovation is a new and very cost-effective technology for local delivery of biological drugs. Human therapeutic proteins are delivered on site by living lactic acid bacteria acting like small bioreactors, for example in skin wounds or in the colon of the intestine. We have a freeze-dried formulation with good stability. The lactic acid bacteria are revived immediately prior use by addition of a small volume of water.
Results to date
Project results, scientific results and milestones are achieved and reached continuously, most of times in accordance with our execution plan. The project started 2012 and follow regulations in drug development. Next steps are to conduct a toxicology study in large animals and to produce a industrial scale batch of the material to be used in the first clinical trial with our lead candidate EV100 assessing safety and efficacy as a topical treatment to accelerate wound healing. The project have received multiple grants and awards and we are now in the first seed financing round.
Benefits of EIT Health support
One of the challenges with this project is the regulatory part since the drug candidates are advanced therapy medicinal products and at the same time being living organisms.
"With funding from the PoC Head start grant we were able to sign and work with three very senior regulatory experts in the fields of ATMPS, strategy and manufacturing processes which made the project progress in the right direction. Being selected from tough competition as the winner of EIT Health Summit 2016 BPA we got a lot of visibility beyond Scandinavia and were able to extend our international network and met many new relevant current and future partners," according to CEO Evelina Vågesjö.
"Being invited by EIT Health to be one of a handful of European start-ups to pitch at two international events – the EIT Health Journalists Thematic Network Meeting in Paris, May 2017 and the Global Investors Forum in Boston, USA, October 2017 – has given the company further exposure and unique opportunities to introduce the project to the international community and press."
Vision & goals
Ilya Pharma will revolutionize the field of wound care and be a significant part in development of next generation biologicals, innovating well beyond protein- and antibody-based medicinal products.
There are today 12 people working with the project and the background of the team members range from senior industrial executive positions in pharma, to world leading academic achievements to PhD-students and hungry entrepreneurs with combined science and business background. The 4 founders and core team are Evelina Vågesjö, PhD, CEO, Mia Phillipson, Professor, CSO, Stefan Roos Ass. Professor, CTO and Göran Beijer, Chairman of the Board.
Founding Year: 2016
Location: Uppsala, Sweden
Contact: Evelina Vågesjö, CEO.